Overview

Ketamine vs. Placebo as Adjunctive Therapies for Severe Alcohol Withdrawal

Status:
Withdrawn
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the addition of ketamine to dexmedetomidine as adjunctive therapies of severe alcohol withdrawal in medical ICU patients. Specifically, this study will assess whether the combination of ketamine and dexmedetomidine reduces the doses of conventional agents used for alcohol withdrawal while maintaining patient comfort and safety and will explore if the combination alters the expression of catecholamines in the serum over time.
Phase:
Phase 4
Details
Lead Sponsor:
University of Colorado, Denver
Treatments:
Dexmedetomidine
Ethanol
Ketamine